Comparative Pharmacology
Head-to-head clinical analysis: AMONDYS 45 versus QALSODY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMONDYS 45 versus QALSODY.
AMONDYS 45 vs QALSODY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amondys 45 (casimersen) is a phosphorodiamidate morpholino oligomer that binds to exon 45 of dystrophin pre-mRNA, excluding it during splicing to restore the mRNA reading frame in Duchenne muscular dystrophy (DMD) patients with amenable mutations. This enables production of internally truncated but functional dystrophin protein.
QALSODY (tofersen) is an antisense oligonucleotide that mediates degradation of SOD1 mRNA through RNase H activity, reducing SOD1 protein production.
Intravenous infusion over 35-60 minutes: 30 mg/kg once every 7 days.
100 mg intrathecally once every 4 weeks. Administer as a loading dose of 100 mg on days 0, 14, and 28, then every 4 weeks thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 3.6 hours, necessitating frequent dosing (weekly) to maintain therapeutic levels.
Terminal elimination half-life is approximately 28 days (range 22-35 days) following intrathecal administration; this prolonged half-life supports monthly dosing schedules and reflects slow clearance from the central nervous system.
Primarily renal, with 100% of the dose excreted as unchanged drug in urine.
Primarily excreted unchanged in urine via glomerular filtration and tubular secretion, accounting for approximately 60-70% of the administered dose; biliary/fecal excretion accounts for the remainder (30-40%) as inactive metabolites and parent drug.
Category C
Category C
Antisense Oligonucleotide
Antisense Oligonucleotide